You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Dow
Boehringer Ingelheim
Medtronic
McKesson

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LY3039478


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Clinical Trials for LY3039478

Trial ID Title Status Sponsor Phase Summary
NCT01695005 A Study of LY3039478 in Participants With Advanced Cancer Recruiting Eli Lilly and Company Phase 1 The purpose of this study is to find a recommended dose level of LY3039478 that can safely be taken by participants with advanced cancer or cancer that has spread to other parts of the body, including but not limited to lymphoma. The study will also explore changes to various markers in blood cells and tissue. Finally, the study will help to document any tumor activity this drug may have.
NCT02518113 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Recruiting Eli Lilly and Company Phase 1/Phase 2 The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).
NCT02659865 A Study of LY3039478 in Healthy Participants Completed Eli Lilly and Company Phase 1 The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods. Either LY3039478 or placebo will be given once by mouth in each period. Part B has two periods. Participants will receive both formulations of LY3039478, by mouth, over the course of the study. Both parts of the study will also explore how much LY3039478 gets into the bloodstream and how long it takes the body to get rid of it. Information about any side effects will also be collected. Participants may only enroll in one part. The study will last at least 33 days, not including screening. Screening must be performed up to 30 days before enrollment. Part B was added by protocol amendment approved in April, 2016.
NCT02784795 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Recruiting Eli Lilly and Company Phase 1 The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
NCT02836600 A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Recruiting Eli Lilly and Company Phase 1 The purpose of this study is to evaluate the tolerability of the study drug LY3039478 in Japanese participants with advanced solid tumors.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for LY3039478

Condition Name

Condition Name for
Intervention Trials
Healthy 3
T-cell Lymphoblastic Lymphoma 1
Advanced Solid Tumor 1
Neoplasm Metastasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Leukemia, Lymphoid 1
Neoplasms, Plasma Cell 1
Neoplasms 1
Multiple Myeloma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for LY3039478

Trials by Country

Trials by Country for
Location Trials
United States 20
France 3
United Kingdom 2
Spain 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
New York 3
Michigan 3
Massachusetts 3
Florida 3
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for LY3039478

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 1/Phase 2 1
Phase 1 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 7
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for LY3039478

Sponsor Name

Sponsor Name for
Sponsor Trials
Eli Lilly and Company 7
Fred Hutchinson Cancer Research Center 1
National Cancer Institute (NCI) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 7
NIH 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Harvard Business School
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.